Claims for Patent: 10,545,138

Summary for Patent: 10,545,138

Title:	Stable nanomagnetic particle dispersions
Abstract:	Processes and compositions are described for preparing new, colloidally stable, coated nanomagnetic particles useful for both in-vitro and in-vivo biomedical applications, including cell targeting and capturing cells, microorganisms, and cellular organelles or entities such as exosomes. These nanomagnetic particles can also be used as imaging contrast agents due to their small size and high magnetic moment. The nanomagnetic particles include a series of sequentially added, stabilizing surface coatings rendered onto nano-sized magnetic crystal clusters (e.g., magnetite particles) to impart colloidal stability in complex biological samples with minimal leaching of the coating materials, high binding capacity, and low non-specific binding. Another benefit of this invention is the ability to utilize both external and internal magnetic field-generating separation devices to effect separation of the magnetic nanoparticles.
Inventor(s):	Gohel; Dhanesh (San Diego, CA), Zhang; Hong (La Jolla, CA), Ransom; John (Encinitas, CA)
Assignee:	BioLegend, Inc. (San Diego, CA)
Application Number:	15/143,552
Patent Claims:	1. A targeted nanomagnetic particle, comprising: (a) a magnetic core particle; (b) a glass layer encapsulating the magnetic core particle; (c) a protein/polymer composite layer bound to the glass layer, wherein the protein/polymer composite layer i) comprises serum albumin and ii) is covalently bound to the glass layer; and (d) a targeting moiety that comprises one member of a bioaffinity ligand pair covalently conjugated to the serum albumin in the protein/polymer composite layer, wherein the targeted nanomagnetic particle has a diameter ranging from about 30 nm to about 300 nm. 2. A targeted nanomagnetic particle according to claim 1, wherein the magnetic core particle comprises a ferrous oxide; a chromium oxide; or a stable metal oxide that comprises a substituted metal ion selected from the group consisting of Mn, Co, Ni, Zn, Gd, and Dy. 3. A targeted nanomagnetic particle according to claim 1, wherein the glass layer is a silane layer formed from organofunctional alkoxysilane molecules. 4. A targeted nanomagnetic particle according to claim 1, wherein the targeting moiety is selected from the group consisting of an antibody, an antigen-binding antibody fragment, a cell surface receptor, a ligand-binding extracellular domain of a cell surface receptor, a nucleic acid, avidin, streptavidin, and biotin. 5. A targeted nanomagnetic particle according to claim 1 that further comprises a detectable label. 6. A targeted nanomagnetic particle according to claim 2, wherein the magnetic core particle comprises magnetite (Fe.sub.3O.sub.4) crystals. 7. A composition comprising a plurality of targeted nanomagnetic particles according to claim 1. 8. A composition according to claim 7 that is a dry and readily dispersible or liquid composition. 9. A composition according to claim 7, wherein the plurality of targeted nanomagnetic particles comprises a plurality of targeted nanomagnetic particle species, wherein each targeted nanomagnetic particle species comprises a different targeting moiety species. 10. A kit comprising a composition according to claim 7 in a container and instructions for use of the composition. 11. A targeted nanomagnetic particle according to claim 6, wherein the magnetite crystals have a diameter ranging from about 5 nm to about 300 nm. 12. A targeted nanomagnetic particle according to claim 3, wherein the organofunctional alkoxysilane molecules comprise a couplable end group. 13. A targeted nanomagnetic particle according to claim 12, wherein the couplable end group is selected from the group consisting of an amino, sulphydryl, carboxyl, and hydroxyl end group. 14. A targeted nanomagnetic particle according to claim 1, wherein the protein/polymer composite layer further comprises one or more of dextran and casein. 15. A targeted nanomagnetic particle according to claim 1, wherein the serum albumin comprises bovine serum albumin or human serum albumin. 16. A targeted nanomagnetic particle according to claim 1, wherein the protein/polymer composite layer is permanently bound by heating to a temperature from about 45.degree. C. to about 85.degree. C. 17. A targeted nanomagnetic particle according to claim 2, wherein the ferrous oxide is Fe.sub.3O.sub.4 or Fe.sub.2O.sub.3. 18. A targeted nanomagnetic particle according to claim 2, wherein the chromium oxide is CrO.sub.3.

Details for Patent 10,545,138

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2040-01-28
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2040-01-28
Csl Behring Llc	ALBUMINAR, ALBUMINAR-20, ALBUMINAR-25, ALBUMINAR-5	albumin (human)	Injection	103955	03/17/2000		2040-01-28
Csl Behring Llc	ALBUMINAR, ALBUMINAR-20, ALBUMINAR-25, ALBUMINAR-5	albumin (human)	Injection	103955	07/17/2000		2040-01-28
Octapharma Pharmazeutika Produktionsges.m.b.h.	N/A	albumin (human)	Injection	125154	10/17/2006		2040-01-28